|Security||CMPGY / Compass Group Plc (20449X302)|
|Institutional Value||$ 1,283,052,000 USD|
Institutional Stock Ownership and Shareholders
Compass Group Plc (OTC:CMPGY) has 19 institutional investors and shareholders that have
filed 13D/G or 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 3,144,657 shares.
Largest shareholders include
Parametric Portfolio Associates Llc, Aristotle Capital Management, LLC, Silvercrest Asset Management Group Llc, Scout Investments, Inc., Geneva Advisors, LLC, Paradigm Asset Management Co Llc, Northroad Capital Management Llc, World Asset Management Inc, Chartwell Investment Partners, Llc, and Hartwell J M Limited Partnership.
Compass Group Plc (OTC:CMPGY) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.
|FTB Advisors, Inc.||359||181||-49.58||7||3||-57.14|
|HARTWELL J M LIMITED PARTNERSHIP||21,784||21,784||0.00||454||472||3.96|
|PARAMETRIC PORTFOLIO ASSOCIATES LLC||1,680,340||1,821,915||8.43||35,010||39,444||12.66|
|PNC FINANCIAL SERVICES GROUP, INC.||7,401||7,487||1.16||151||160||5.96|
|Sonora Investment Management, LLC||70||70||0.00||1,458||2||-99.86|
|World Asset Management Inc||62,999||47,475||-24.64||1,313||1,014||-22.77|
|PARADIGM ASSET MANAGEMENT CO LLC||56,937||56,937||0.00||1,162,526||1,216,644||4.66|
|QUADRANT CAPITAL GROUP LLC||7,438||7,253||-2.49||146||146||0.00|
|SCOUT INVESTMENTS, INC.||154,172||146,944||-4.69||3,148||3,140||-0.25|
|Gemmer Asset Management LLC||99||76||-23.23||2||2||0.00|
|SILVERCREST ASSET MANAGEMENT GROUP LLC||151,589||154,782||2.11||3,158||3,351||6.11|
|GLENMEDE TRUST CO NA||2,972||0||-100.00||64||0||-100.00|
|Vigilant Capital Management, LLC||981||21|
|CHARTWELL INVESTMENT PARTNERS, LLC||23,253||497|
|Aristotle Capital Management, LLC||730,240||735,456||0.71||14,910||15,715||5.40|
|Lenox Wealth Management, Inc.||398||9|
|Private Capital Group, Llc||2,327||2,526||8.55||48||55||14.58|
|Lenox Wealth Advisors, Inc.||0||404||0||9|
|NORTHROAD CAPITAL MANAGEMENT LLC||193,086||56,856||-70.55||3,688||1,104||-70.07|
|Geneva Advisors, LLC||60,200||59,879||-0.53||1,136||1,264||11.27|
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
Related News Stories
The following slide deck was published by Compass Group Plc ADR in conjunction with this event.
London: A tycoon killed with his family in a seaplane crash in the Hawkesbury River on New Year's Eve has left a £41 million ($72 million) fortune to the crisis-hit charity Oxfam, a British newspaper reported on Tuesday.
AWC Bhd (Aug 10, 78 sen) Maintain buy with a higher target price of RM1.04 from 78 sen: We remain bullish after our meeting with management. The change in government will not impede facility management business sentiments. Instead, AWC is poised to benefit from cost-tightening measures.
Could we see an increased market focus on quality and valuation as the strong earnings upgrade cycle appears to fade?
Good morning. And welcome to Compass Diversified Holdings' 2018 Second Quarter Conference Call. Today's call is being recorded. All lines have been placed on mute. [Operator Instructions] At this time, I would like to turn the conference over to Leon Berman of the IGB Group for introductions and the reading of the Safe Harbor statement. Please go ahead, sir.
as of ET